Comparative sensitivities betweendifferent plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure

Hunt, 2001, Circulation, 104, 2996, 10.1161/hc4901.102568 Fonarow, 2003, Prevention of heart failure: Effective strategies to combat the growing epidemic, Rev Cardiovasc Med, 4, 8 Wang, 2003, The epidemiology of “asymptomatic” left ventricular systolic dysfunction: Implications for screening, Ann Intern Med, 138, 907, 10.7326/0003-4819-138-11-200306030-00012 Davies, 2001, Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: A population basedstudy, Lancet, 358, 439, 10.1016/S0140-6736(01)05620-3 Redfield, 1994, Natural history of incidentally discovered, asymptomatic idiopathic dilated cardiomyopathy, Am J Cardiol, 74, 737, 10.1016/0002-9149(94)90323-9 Wang, 2003, Natural history of asymptomatic left ventricular systolic dysfunction in the community, Circulation, 108, 977, 10.1161/01.CIR.0000085166.44904.79 Rodeheffer, 2004, Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?, J Am Coll Cardiol, 44, 740 Freitag, 2003, Screening for left ventricular systolic dysfunction: The use of B-type natriuretic peptide, Heart Fail Monit, 4, 38 Hobbs, 2004, Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations, Heart, 90, 866, 10.1136/hrt.2003.014258 Bibbins-Domingo, 2004, Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study, Am J Med, 116, 509, 10.1016/j.amjmed.2003.08.037 McDonagh, 1998, Biochemical detection of left-ventricular systolic dysfunction, Lancet, 351, 9, 10.1016/S0140-6736(97)03034-1 Nakamura, 2002, Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population, Heart, 87, 131, 10.1136/heart.87.2.131 Nakamura, 2003, The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients, Am J Hypertens, 16, 1025, 10.1016/j.amjhyper.2003.07.024 Ng, 2003, Identification of previously undiagnosed left ventricular systolic dysfunction: Community screening using natriuretic peptides and electrocardiography, Eur J Heart Fail, 5, 775, 10.1016/S1388-9842(03)00154-5 Pfister, 2004, Use of NT proBNP in routine testing and comparison to BNP, Eur J Heart Fail, 6, 289, 10.1016/j.ejheart.2003.12.012 Suzuki, 2000, Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels, Jpn Heart J, 41, 205, 10.1536/jhj.41.205 Redfield, 2004, Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: A communitybased study, Circulation, 109, 3176, 10.1161/01.CIR.0000130845.38133.8F Tang, 2003, Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure, Circulation, 108, 2964, 10.1161/01.CIR.0000106903.98196.B6 Wu, 2004, Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: A multisite study, Clin Chem, 50, 867, 10.1373/clinchem.2003.026138 Mueller, 2004, Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay, Clin Chem, 50, 1104, 10.1373/clinchem.2004.031484 Wu, 2003, Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure, Am J Cardiol, 92, 628, 10.1016/S0002-9149(03)00741-0 Hammerer-Lercher, 2004, Natriuretic peptides as markers of mild forms of left ventricular dysfunction: Effects of assays on diagnostic performance of markers, Clin Chem, 50, 1174, 10.1373/clinchem.2003.028316 Mueller, 2004, Biochemical diagnosis of impaired left ventricular ejection fraction—comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) andamino terminal proBNP (NT-proBNP), Clin Chem Lab Med, 42, 159, 10.1515/CCLM.2004.029 Vasan, 2002, Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham Heart Study, JAMA, 288, 1252, 10.1001/jama.288.10.1252 McDonagh, 2004, NT-proBNP and the diagnosis of heart failure: A pooled analysis of three European epidemiological studies, Eur J Heart Fail, 6, 269, 10.1016/j.ejheart.2004.01.010 Atisha, 2004, A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction, Am Heart J, 148, 518, 10.1016/j.ahj.2004.03.014 Bhalla, 2004, Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus, J Am Coll Cardiol, 44, 1047, 10.1016/j.jacc.2004.05.071 Cosson, 2004, Usefulness of B-type natriuretic peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus, Diabetes Metab, 30, 381, 10.1016/S1262-3636(07)70132-5 Magnusson, 2004, Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease, Diabetes Care, 27, 1929, 10.2337/diacare.27.8.1929 Wu, 2004, The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: An analysis from the Breathing Not ProperlyMultinational Study, Diabetes Care, 27, 2398, 10.2337/diacare.27.10.2398 Epshteyn, 2003, Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes, Diabetes Care, 26, 2081, 10.2337/diacare.26.7.2081 Ray, 2004, Usefulness of Btype natriuretic peptide in elderly patients with acute dyspnea, Intensive Care Med, 30, 2230, 10.1007/s00134-004-2469-0 Ueda, 2003, Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons, Am J Med, 114, 266, 10.1016/S0002-9343(02)01525-5 Baker, 2003, Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure, Am Heart J, 146, 736, 10.1016/S0002-8703(03)00396-X Heidenreich, 2004, Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction, J Am Coll Cardiol, 43, 1019, 10.1016/j.jacc.2003.10.043 Vourvouri, 2003, Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device, Eur J Heart Fail, 5, 767, 10.1016/S1388-9842(03)00155-7